Xeomin 100 IU Injection contains Clostridium botulinum toxin type A used for several therapeutic and aesthetic purposes.

Brand Name: Xeomin

Composition: Clostridium botulinum toxin type-A

Mechanism of Action:

Xeomin slows muscle contraction by preventing acetylcholine from being released at the neuromuscular junction. Temporary muscle paralysis results, which lessens dynamic wrinkles and manages muscle spasms.

Uses:

• Chronic migraine
• Cervical dystonia (neck muscle spasms)
• Blepharospasm (eyelid spasms)

Dosage and Administration:

The indication determines the dosage and course of treatment. Small amounts are usually injected into particular muscles for cosmetic purposes. administered by a trained medical professional by intramuscular injection.

Side Effects:

• Localized pain, swelling, or bruising at the injection site
• Headache
• Muscle weakness
• Fever
• Nausea
• Vomiting
• Dizziness
• Allergic reactions
• Vision problems
• Difficulty swallowing

Safety Advise:

Lungs  

The safety of Xeomin 100IU Injection for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Xeomin 100IU Injection for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Xeomin 100IU Injection for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Xeomin should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Xeomin while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Storage:

Xeomin should be kept in the refrigerator between 2°C and 8°C (36°F and 46°F). The formulation may be harmed by freezing, so avoid doing so.

References:

1.  Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiology and immunology. 1995;39(3):161-8.

2.  Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. Journal of neurology. 1992 Jan;239:16-20.

3.   Oguma K, Fujinaga Y, Inoue K. Clostridium botulinum toxin. Journal of Toxicology: Toxin Reviews. 1997 Jan 1;16(4):253-66.

4.  Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Movement disorders: official journal of the Movement Disorder Society. 2004 Mar;19(S8):S53-9.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Modi Mundi Pharma Pvt Ltd

Address: Ground Floor Modi Tower, 98, Nehru Place, New Delhi, Delhi 110019

Country of origin: India